Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced it presented new preclinical data from
its investigational BCL6 PROTAC® degrader ARV-393 at the
European Hematology Association (EHA) 2024 Annual Congress that
took place June 13-16, 2024 in Madrid, Spain, and presented new
preclinical data from its PROTAC LRRK2 degrader program at the
Biennial International LRRK2 Meeting that took place June 18-21,
2024 in Crete, Greece.
Data presented at EHA showed anti-tumor activity for the
company’s investigational PROTAC BCL6 degrader, ARV-393, in
preclinical models of B-cell lymphoma. In these preclinical models,
ARV-393 potently and rapidly degraded the BCL6 protein and
inhibited cell growth in diffuse large B-cell lymphoma (DLBCL) and
Burkitt cell lines. ARV-393 showed tumor growth inhibition,
including tumor regression, in various DLBCL cell line-derived
xenograft (CDX) models and in multiple patient-derived xenograft
(PDX) models of non-Hodgkin lymphoma (NHL), including germinal
center B-cell-like (GCB), activated B-cell (ABC), GCB/ABC, BCL not
otherwise specified (BCL/NOS) subtypes of DLBCL, and Burkitt
lymphoma.
“These new preclinical data for ARV-393 demonstrate that in
these models it can effectively target and induce the degradation
of the BCL6 protein that is commonly deregulated in DLBCL,” said
John Houston, Ph.D., Chairperson, President, and Chief Executive
Officer at Arvinas. “These encouraging results suggest that ARV-393
could be developed into a potential new treatment for patients with
certain types of non-Hodgkin lymphoma, particularly those who have
not responded to other treatments."
Preclinical data presented at the Biennial LRRK2 Meeting
highlighted the potential of the company’s oral PROTAC LRRK2
degraders to treat neurodegenerative diseases. Preclinical studies
in mice demonstrated full target engagement of LRRK2 kinase
inhibitor and near-complete LRRK2 degradation with PROTAC LRRK2
degraders, but substantially less Type II pneumocyte enlargement
compared to an experimental LRRK2 kinase inhibitor. In addition,
the more noticeable Type II pneumocyte enlargement phenotype
observed with the experimental LRRK2 kinase inhibitor was
substantiated by the accumulation of surfactant protein C in lung,
which was not observed after treatment with a PROTAC LRRK2
degrader.
“Nonclinical findings presented this week suggest the potential
for a wide therapeutic index and manageable safety profile for
PROTAC degraders versus experimental LRRK2 kinase inhibitors,” said
Angela Cacace, Ph.D., Chief Scientific Officer at Arvinas. “In
earlier preclinical studies, Arvinas’ PROTAC LRRK2 degraders have
been shown to cross the blood-brain barrier and degrade LRRK2, a
large multidomain scaffolding kinase, in deep brain regions.”
Arvinas’ oral PROTAC BCL6 degrader ARV-393 is currently in a
phase 1 clinical trial in patients with NHL, and Arvinas also has
an oral PROTAC LRRK2 degrader, ARV-102, currently being
investigated in a phase 1 clinical trial in healthy volunteers.
About ARV-393
ARV-393 is an investigational PROTAC designed to degrade B-cell
lymphoma 6 protein (BCL6), a transcriptional repressor and major
driver of B-cell lymphomas. The BCL6 protein facilitates B cell
tolerance of rapid proliferation and somatic gene recombination via
repressing cell cycle checkpoints, terminal differentiation,
apoptosis, and the DNA damage response. PROTAC-mediated degradation
has the potential to address the traditional undruggable nature of
BCL6. ARV-393 is currently in a phase 1 clinical trial in patients
with non-Hodgkin lymphoma.
About ARV-102
ARV-102 is an investigational PROTAC designed to degrade
Leucine-rich repeat kinase 2 (LRRK2) which is a large multidomain
scaffolding kinase. Human genetics, increased activity and
expressions of LRRK2 is genetically involved in the pathogenesis of
neurological diseases including Parkinson’s Disease and progressive
supranuclear palsy. Arvinas is developing oral, blood-brain-barrier
penetrant PROTAC degraders of LRRK2.
About ArvinasArvinas (Nasdaq: ARVN) is a
clinical-stage biotechnology company dedicated to improving the
lives of patients suffering from debilitating and life-threatening
diseases. Through its PROTAC (PROteolysis Targeting Chimera)
protein degrader platform, the Company is pioneering the
development of protein degradation therapies designed to harness
the body’s natural protein disposal system to selectively and
efficiently degrade and remove disease-causing proteins. Arvinas is
currently progressing multiple investigational drugs through
clinical development programs, including vepdegestrant, targeting
estrogen receptor for patients with locally advanced or metastatic
ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for
neurodegenerative disorders; and ARV-393, targeting BCL6 for
relapsed/refractory non-Hodgkin Lymphoma. Arvinas is headquartered
in New Haven, Connecticut. For more information about Arvinas,
visit us on www.arvinas.com, which does not form part of this
release, and connect with us on LinkedIn and X.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties, including statements regarding
the potential for Arvinas’ investigational BCL6 PROTAC degrader
ARV-393 as a new treatment for patients with certain types of
non-Hodgkin lymphoma, particularly those who have not responded to
other treatments and its potential to address the traditional
undruggable nature of BCL6; and the potential for Arvinas’
investigational PROTAC LRRK2 degraders (including ARV-102) to treat
neurodegenerative diseases , and the potential for a wide
therapeutic index and manageable safety profile. All statements,
other than statements of historical facts, contained in this press
release, including statements regarding Arvinas’ strategy, future
operations, future financial position, future revenues, projected
costs, prospects, plans and objectives of management, are
forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. and
objectives of management, are forward-looking statements. The words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“might,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words.
Arvinas may not actually achieve the plans, intentions or
expectations disclosed in these forward-looking statements, and you
should not place undue reliance on such forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements Arvinas makes as a result of various risks and
uncertainties, including but not limited to: whether Arvinas will
be able to successfully conduct and complete development for its
product candidates, including ARV-393 and ARV-102, including
whether Arvinas initiates and completes clinical trials for its
product candidates and receives results from its clinical trials on
its expected timelines or at all; Arvinas’ ability to protect its
intellectual property portfolio; whether Arvinas’ cash and cash
equivalent resources will be sufficient to fund its foreseeable and
unforeseeable operating expenses and capital expenditure
requirements; and other important factors discussed in the “Risk
Factors” section of Arvinas’ Annual Report on Form 10-K for the
year ended December 31, 2023 and subsequent other reports on file
with the U.S. Securities and Exchange Commission. The
forward-looking statements contained in this press release reflect
Arvinas’ current views with respect to future events, and Arvinas
assumes no obligation to update any forward-looking statements,
except as required by applicable law. These forward-looking
statements should not be relied upon as representing Arvinas’ views
as of any date subsequent to the date of this release.
Contacts
Investor Contact:Jeff Boyle, Arvinas Investor
Relations+1 (347) 247-5089Jeff.Boyle@arvinas.com
Media Contact:Kirsten Owens, Arvinas
Communications+1 (203) 584-0307 Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From May 2024 to Jun 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Jun 2023 to Jun 2024